CLINICAL TRIALS PROFILE FOR SEASONIQUE
✉ Email this page to a colleague
All Clinical Trials for SEASONIQUE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00117273 ↗ | A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens | Completed | Duramed Research | Phase 3 | 2005-06-01 | This is a randomized, open-label study to evaluate pituitary ovarian suppression in healthy, reproductive-aged women using three different regimens of oral contraceptives (OCs). Two extended regimen OCs, Seasonale (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 84 days followed by 7 days of placebo), and Seasonique (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 84 days followed by 7 days of ethinyl estradiol 0.01 mg), and a 28-day regimen OC, Portia (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 21 days followed by 7 days of placebo). |
| NCT00196313 ↗ | A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain | Completed | Duramed Research | Phase 2 | 2005-05-01 | This study is being conducted to evaluate the effects of treatment with Seasonique an extended-regimen oral contraceptive that utilizes low dose ethinyl estradiol during the typical hormone-free interval. Patients will receive 13 weeks of treatment with the option to extend blinded therapy for an additional 13 weeks. The overall study duration will be 6-9 months. Patients will be required to record menstrual pain in a daily diary. |
| NCT00196352 ↗ | A Multicenter Study to Evaluate the Safety of Seasonique, an Oral Contraceptive. | Completed | Duramed Research | Phase 3 | 2003-05-01 | This study is being conducted to evaluate the safety of ethinyl an extended-regimen oral contraceptive, with ethinyl estradiol supplementation during the usual hormone-free week, for up to an additional three consecutive years. |
| NCT00196365 ↗ | A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain | Completed | Duramed Research | Phase 3 | 2005-01-01 | This study is being conducted to evaluate the effects of treatment with Seasonique an extended-regimen oral contraceptive that utilizes low dose ethinyl estradiol during the typical hormone-free interval. Patients will receive 26 weeks of treatment. The overall study duration will be approximately 9 months. Patients will be required to record menstrual pain in a daily diary. |
| NCT00781456 ↗ | A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches | Completed | Duramed Research | Phase 2 | 2009-01-01 | This study is being conducted to evaluate the efficacy of a 91-day extended cycle oral contraceptive compared to placebo for decreasing the frequency and severity of menstrually-related migraine headaches. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SEASONIQUE
Condition Name
Clinical Trial Locations for SEASONIQUE
Trials by Country
Clinical Trial Progress for SEASONIQUE
Clinical Trial Phase
Clinical Trial Sponsors for SEASONIQUE
Sponsor Name
